Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin Plans Byetta sNDA Submission For Expanded Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

The sNDA for use of exenatide in patients on thiazolidinediones will likely be submitted to FDA in mid-2006.

You may also be interested in...



Amylin To Celebrate New Year With New Byetta Claim For Use With TZDs

Phase III monotherapy data are expected in late 2007, partner Lilly tells “The Pink Sheet” DAILY.

Amylin To Celebrate New Year With New Byetta Claim For Use With TZDs

Phase III monotherapy data are expected in late 2007, partner Lilly tells “The Pink Sheet” DAILY.

Lilly/Amylin’s Byetta Type 2 Diabetes Therapy To Launch June 1

Amylin will put 325 reps behind exenatide, in addition to a Lilly sales force. The firms will target 60,000 physicians in first six months. First-in-class gut hormone follows approval of Amylin’s diabetes therapy Symlin in March.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel